Menu

In the News

PHI CEO Mary Pittman Named One of Sixteen Women Who Changed Public Health

Marking 150 Years of Women at the University of California Berkeley, the university highlighted 16 women who exemplify the best of Berkeley Public Health, including PHI CEO Mary Pittman, who was featured for her work in addressing health inequities.

  • Berkeley Public Health
Mary Pittman, "16 women who changed public health"

Marking 150 Years of Women at the University of California Berkeley, the University highlighted 16 women who exemplify the best of Berkeley Public Health, including PHI CEO Mary Pittman, who was featured for her work in addressing health inequities.

Mary was noted as a nationally recognized leader in improving community health—with a DrPH from Berkeley Public Health—and the president and CEO of president and chief executive officer of the Public Health Institute (PHI),  where she mobilizes health professionals to impact national and global public policy.

Before joining PHI, Pittman served as the president and CEO of the California Association of Public Hospitals and a director of the San Francisco Department of Public Health.

Click below to see all sixteen profiles on the Berkeley Public Health website.

Originally published by UC Berkeley Public Health


More Updates

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.

Donate

Find Employment

Begin your career at the Public Health Institute.

See Jobs

Close

Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).

More

Continue to PHI.org